UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, DC D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~Securities~~Date ~~Exchange~~of ~~Act~~Report (Date of ~~1934~~earliest event reported): June 27, 2013

~~Date~~Magnolia ofSolar ~~report (Date of earliest event reported): December 7, 2011~~Corporation

CHINA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

Nevada	~~000~~333-~~52763~~151633	2039-~~2638087~~2075693
(State or Other Jurisdiction	(Commission File Number)	(IRS Employer
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
of Incorporation)		Identification No.)

24th Floor, Building A, Zhengxin Mansion, No. 5 of 1st Gaoxin Road Hi-Tech Development Zone, Xi’an City, PRC (Address of Principal Executive Offices)

54 Cummings Park Suite 316 Woburn, MA		01801
(Address of principal executive offices)		(Zip Code)

Registrant'’s telephone number, including area code: (86781) 29497-~~84067215~~2900

~~Check~~(Former ~~the~~name ~~appropriate~~or ~~box~~former ~~below~~address, if ~~the~~changed ~~Form~~since ~~8-K~~last ~~filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below~~report):

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 81.01. ~~Other~~Entry ~~Events~~into a Material Definitive Agreement.

AsOn ~~was~~June ~~previously disclosed~~27, ~~ValueRich~~2013, ~~Inc.~~Magnolia ~~(“ValueRich”)~~Solar ~~commenced~~Corporation ~~a private arbitration against~~ (the “Company”) ~~in Florida asserting breach of contract, conversion,~~ and ~~unjust~~holders ~~enrichment claims arising out~~ of aSecond ~~Consulting~~Amended ~~Agreement between ValueRich~~ and ~~Xi’an~~Restated ~~Qinba~~Original ~~Pharmaceuticals~~Issue ~~Co.~~Discount ~~Ltd.~~Senior ~~(“Qinba”),~~Secured ~~which~~Convertible isPromissory ~~the~~Notes ~~operating~~in ~~entity that a Company’s wholly owned subsidiary has a contractual Entrust Management Relationship. ValueRich asserts that~~ the ~~Company~~aggregate ~~breached~~principal ~~and~~amount ~~circumvented the Consulting Agreement by terminating it and becoming a public entity through other means. ValueRich seeks specific performance to obtain 20%~~ of ~~the Company’s outstanding shares~~$1, or000,000 inagreed ~~the alternative, unspecified monetary damages equal~~ to extend the ~~value~~maturity ofdate ~~20%~~ of the ~~Company’s~~notes ~~outstanding~~from ~~shares~~June 30, ~~attorneys’~~2013 ~~fees,~~to ~~arbitration~~December ~~costs~~31, ~~and interest~~2013.

OnCopies ~~December~~of 6,the ~~2011,~~agreements extending the ~~Arbitrator~~notes ~~heard~~are aattached ~~hearing~~hereto onas ~~ValueRich’s~~Exhibit ~~claims~~10.1 and 10.2 and are incorporated herein by reference.

~~On December 7, 2011, the Company received the arbitration decision, in which the Arbitrator awarded 1,125,000 registered shares of the Company to ValueRich for past work performed~~Item 2.03 ToCreation ~~the knowledge~~ of ~~the~~a ~~Company,~~Direct ~~the~~Financial ~~award~~Obligation ~~has~~or ~~not~~an ~~been~~Obligation ~~confirmed~~under inan aOff-Balance ~~court~~Sheet ofArrangement ~~competent jurisdiction as~~ of ~~the~~a ~~date of this report~~Registrant.

~~This~~The information ~~shall~~described ~~not~~above beunder ~~deemed~~ “~~filed”~~Item ~~for~~1.01 ~~purposes~~Entry ofinto ~~Section~~a 18Material ofDefinitive ~~the Securities Exchange Act of 1934, as amended (the “Exchange Act~~Agreement”), oris incorporated byherein ~~reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth~~ by ~~specific~~ reference ~~in such a filing~~.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

	10.1		Agreement to Extend Second Amended and Restated Original Issue Discount Senior Secured Convertible Promissory Note held by Paragon Capital LP

	10.2		Agreement to Extend Second Amended and Restated Original Issue Discount Senior Secured Convertible Promissory Note held by Paragon Capital Offshore LP

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the ~~registrant~~Registrant has duly caused this report to be signed on its behalf by the undersigned ~~hereunto~~thereunto duly authorized.

	CHINA PHARMACEUTICALS, INC.
	MAGNOLIA SOLAR CORPORATION
Date: December 13, 2011	By:	/s/ Guozhu Wang
Date: July 1, 2013	By:	/s/ Dr. Yash R. Puri
		Guozhu Wang
		Name: Dr. Yash R. Puri
		Chief Executive Officer
		Title: Executive Vice-President and Chief Financial Officer

Filing Compare · China Pharmaceuticals Inc